News
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
But so far, most researchers are reassured as are regulators in the UK, United States and Europe.”Prof Sattar and Dr Cork have unpacked the side effects to be aware of:BlindnessStomach issues‘Ozempic ...
Very interesting data from the latest study and successful share issue. Significant events during the first quarter of 2025In January, Nanexa announced that the company had decided to carry out a dire ...
Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.
President Trump cast himself on the campaign trail as the savior of U.S. oil and gas. His shock treatment of the American economy has left the industry reeling. Since Trump took office, oil ...
Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.
Here’s some groovy news. A mind-bending blast from the past — once hailed as a “wonder drug” that could cure everything from anxiety to addiction — is making a comeback. In the first ...
MEXICO CITY—President Trump is pressuring Mexico to allow deeper U.S. military involvement in the fight against drug cartels, people familiar with the discussions said, making security a ...
Two days after its wide release, “Death County, Pa.” has risen to the top spot of Apple’s ranking for top ‘Podcast Series.’ The six-part series is based on a years-long investigation of ...
But the strongest challenge is expected to come from Lilly's weekly GLP-1 drug Trulicity, which analysts Evaluate Pharma predict could overtake Victoza as the biggest selling GLP-1 by 2022.
Liraglutide, the active ingredient in the older generation of drugs, is already available as a lower-cost generic drug, with products approved in the U.S. and Europe, the memo adds.
22h
Zacks Investment Research on MSNNovo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock UpNovo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results